CORAL GABLES, FL / ACCESSWIRE / October 29,2018 / Frost & Sullivan will be hosting a Growth Innovation Leadership (GIL) briefing titled "2019 Healthcare Predictions Unleashed - Growth Opportunities, Technology, and Trends." The firm already states that Globally, 2019 will be a year of value-based care as we expect the outcomes-based care focus to globalize. Access to affordable and quality care will be a key political agenda for upcoming elections in emerging markets such as Asia, Africa, and Central and Eastern European countries.
"Favorable reimbursement policies for clinically relevant digital health applications will expand care delivery models beyond physical medicine. 2019 will be a reality check for two of the most hyped healthcare technologies of this decade such as artificial intelligence (AI) and blockchain" Following these latest industry trends, companies like Premier Health Group, Inc. (PHGRF)(PHGI.CN), Theratechnologies Inc. (OTC PINK: THERF) (TSX:TH.TO), and Flex Pharma, Inc. (FLKS) are in focus on Monday
Premier Health Group, Inc. (PHGRF)(PHGI.CN) subsidiary, HealthVue is focused on developing proprietary technology to deliver quality healthcare through the combination of connected primary care clinics with telemedicine and artificial intelligence (AI), which is right in line with the areas of interest in the Frost & Sullivan briefing. HealthVue has an ecosystem of currently over 100,000 active patients and have plans to rapidly increase that number both domestically and internationally.
Premier Health Group, Inc. (
According to a Research And Markets report, the market for telemedicine was valued at $ 29.6 Billion in 2017 and is anticipated to grow at a compounded annual rate of approximately 19% during 2017-2022. The reported growth of the market is likely to be driven by increasing adoption of telemedicine, rising incidences of chronic diseases, growing geriatric population, government initiatives, and a shortage of physicians among others.
Theratechnologies Inc. (TH.TO) announced today that Trogarzo® (ibalizumab-uiyk) injection is now included in the most recent version of the treatment guidelines issued by the United States Department of Health and Human Services ("DHHS").
"We are very pleased with these guidelines. They recognize the unique mode of action of Trogarzo® and they confirm its usefulness in patients who cannot decrease their viral load below detection despite being on other antiretrovirals. The DHHS guidelines should give even more traction with physicians and payers in the United States," said Luc Tanguay, Presidentand CEO, Theratechnologies Inc.
Trogarzo® is a CD4-directed post-attachment HIV-1 inhibitor. Trogarzo®, in combination withother antiretroviral(s), is indicated for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in heavily treatment-experienced adults with
Flex Pharma, Inc. (FLKS) is a clinical-stage biotechnology company. The company is developing proprietary treatments to specifically treat cramping and spasticity associated with neurological disorders. The company is conducting Phase 2 randomized, controlled trials for cramps and spasticity associated with the severe neurological diseases of ALS, MS and peripheral neuropathies such as Charcot-Marie-Tooth (CMT). The Company’s lead candidate, FLX-787, is being developed under Fast Track designation for the treatment of severe muscle cramps associated with ALS.
Monday, shares of Flex Pharma have jumped to highs of US$0.63 and have traded on well above average trading volume.
In the company’s last press release, Bill McVicar, Ph.D., Presidentand CEO of Flex Pharma, stated, "We continue to believe in the potential of FLX-787 to reduce painful cramps and spasms in patients with neurologic diseases. However, given the additional development work required to advancea FLX-787-based product, it was in the best interest of our stockholders to stop the ongoing MND and CMT studies, reduce our workforce and assess our strategic alternatives. That assessment is underway and we are working diligently to conserve working capital and enhance stockholder value. While we conduct the assessment, we are continuing to assess the potential of FLX-787 in dysphagia (difficulty swallowing) and to operate the HOTSHOT consumer business."
What Is Stock Price (StockPrice.com)?
Stock Price is defined as the price of a single share of a number of saleable stocks of a public company. A stock price is the highest amount an investor or trader is willing to pay for the stock, or the lowest amount that it can be bought for.
StockPrice.com was created for everyone that wants the latest stock quotes, stock charts, company news, and the best financial content.
At Stock Price (StockPrice.com), you get free stock quotes, up-to-date news, international market data, social interaction and the best financial content that will help you manage your financial life.
Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. JSG Communications, LLC which owns www.StockPrice.com is not registered with any financial or securities regulatory authority and does not provide nor claims to provide investment advice or recommendations to readers of this release.
JSG Communications, LLC, which owns www.StockPrice.com, may from time to time have a position in the securities mentioned herein and may increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice. JSG Communications, LLC, which owns www.StockPrice.com, may be compensated for its services in the form of cash-based compensation or equity securities in the companies it writes about, or a combination of the two. Pursuant to an agreement between MIDAM VENTURES, LLC an affiliate of JSG COMMUNICATIONS LLC and Premier Health Group Inc. we were hired for a period from 10/1/201- 4/1/2018 to publicly disseminate information about Premier Health Group Inc. including on the Website and other media including Facebook and Twitter. We were paid $100,000 (CASH) for & were paid "500,000" shares of restricted common shares. We own zero shares of Premier Health Group Inc., which we purchased in the open market. Once the (6)Six month restriction is complete on 4/1/2018 we plan to sell the "500,000" shares of Premier Health Group Inc. that we hold currently in restricted form during the time the Website and/or Facebook and Twitter Information recommends that investors or visitors to the website purchase without further notice to you. We may buy or sell additional shares of Premier Health Group Inc. in the open market at any time, including before, during or after the Website and Information, provide public dissemination of favorable Information. Please click here for full disclaimer